HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company...
Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials...
New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite...
ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage...
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
HOUSTON, TX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in...
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company...
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical...
THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release...
REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025...
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq:...
Conference Call and Webcast Scheduled for November 6, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct....
Ritedose receives FDA approval for Tobramycin Tobramycin expands nation's largest nebulized drug portfolio. - Generic Tobramycin Inhalation Solution marks the...
Hoag Hospital Newport Beach Philips IntelliVue bedside and transport monitors October 30, 2025 10-year collaboration aims to connect scalable monitoring...
Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross...
$1.5 billion acquisition strengthens global leadership in organ technology and accelerates progress toward making every organ countOXFORD, England and MADISON,...
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity...
-- Posters will review product characterization and manufacturing data on T-knife’s lead program, TK-6302, a supercharged PRAME T cell receptor...
MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage...